Product Name:
CDC7-pT376
Product Number:
ab-pk559
Target Full Name: Cell division cycle 7-related protein kinase
Target Alias: CDC7- related kinase; CDC7L1; Cell division cycle 7; HsCdc7; Hsk1; HuCdc7; Kinase CDC7; MuCdc7
Product Type Specific: Protein kinase phosphosite-specific antibody
Antibody Code: PK558
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: T376
Protein UniProt: O00311
Protein SigNET: O00311
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human CDC7 sequence peptide Cat. No.: PE-04AJE99
Antibody Immunogen Sequence: RAG(pT)PGF(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues R373 to F379; In the protein kinase catalytic domain activation T loop region between subdomains VII and VIII.
Production Method: Corresponds to amino acid residues R373 to F379; In the protein kinase catalytic domain activation T loop region between subdomains VII and VIII.
Antibody Modification: Protein kinase phosphosite-specific antibody
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Very weak immunoreactivity of a target-sized protein by Western blotting in sea star oocytes. Very strong immunoreactivity with immunogen peptide on dot blots.
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 62-67 kDa.
Antibody Specificity: High-very high
Antibody Cross Reactivity: No significant cross-reactive proteins detected in in A431, HeLa and Jurkat cells.
Related Product 1: CDC7-pT376 blocking peptide
Scientific Background: CDC7 is a protein-serine/threonine kinase that is important for the G1/S transition in the cell division cycle. The protein product may phosphorylate critical substrates in G1/S phase transition and DNA replication. CDC7 can also phosphorylate MCM2 and MCM3. It is activated by phosphorylation at T376 in the kinase activation loop by CDK1 and CDK2. It also requires binding to activator of S-phase kinase (ASK)/DBF4B to be fully stimulated. It may be an oncoprotein (OP) as over-expression of CDC7 may be associated with neoplastic tumour transformation. RNAi inhibition of CDC7 induces an abortive S phase and apoptotic cell death in p53-mutant ErbB2-overexpressing and triple-negative (ER-/PR-/ErbB2-) breast cancer cell lines, but not in untransformed breast epithelial cells. Consequently, CDC7 appears to represent a potent and highly specific anticancer target in ErbB2-overexpressing and triple-negative breast cancers. It is also a suitable target for treatment of other types of cancer, including pancreatic cancer.
